![Foto de Daniel](/img/nophoto.png)
Daniel
Castellano-Gauna
Publicacións nas que colabora con Daniel Castellano-Gauna (12)
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
-
BlaDimiR: A Urine-based miRNA Score for Accurate Bladder Cancer Diagnosis and Follow-up
European Urology
-
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34
2020
2019
-
CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of RB1 status
Clinical Cancer Research, Vol. 25, Núm. 1, pp. 390-402
-
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Nature Medicine
2017
-
BMP4 induces M2 macrophage polarization and favors tumor progression in bladder cancer
Clinical Cancer Research, Vol. 23, Núm. 23, pp. 7388-7399
-
Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer
Oncotarget, Vol. 8, Núm. 6, pp. 10531-10542
2015
-
A Polycomb-mir200 loop regulates clinical outcome in bladder cancer
Oncotarget, Vol. 6, Núm. 39, pp. 42258-42275
-
Analysis of the polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer
Clinical Epigenetics, Vol. 7, Núm. 1
-
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors
Molecular Carcinogenesis, Vol. 54, Núm. 7, pp. 566-576
2014
-
In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer
Cancer Research, Vol. 74, Núm. 22, pp. 6565-6577